Search research articles
Contact Us
Filters
Showing results (201-210 of 218) with videos related to
Page
of 22
Sort By:
American Heart Journal
|
June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial
Roberto Bolli, Joshua M Hare, Timothy D Henry, et al.
European Heart Journal
|
September 13, 2013
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis
Ronak Delewi, Alexander Hirsch, Jan G Tijssen, et al.
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Circulation
|
April 1, 2014
Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices
Deborah D Ascheim, Annetine C Gelijns, Daniel Goldstein, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 218) with videos related to
Sort By:
Page
of 22
American Heart Journal
|
June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial
Roberto Bolli, Joshua M Hare, Timothy D Henry, et al.
European Heart Journal
|
September 13, 2013
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis
Ronak Delewi, Alexander Hirsch, Jan G Tijssen, et al.
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Circulation
|
April 1, 2014
Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices
Deborah D Ascheim, Annetine C Gelijns, Daniel Goldstein, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Page
of 22